The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | The role of immunotherapy in cholangiocarcinoma
Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the role of immunotherapy in cholangiocarcinoma. The randomized Phase III TOPAZ-1 (NCT03875235) study investigating first-line gemcitabine plus cisplatin with or without durvalumab patients with advanced biliary tract cancer demonstrated an improvement in overall-survival (OS), progression-free survival (PFS) and response rate with the addition of durvalumab. Although there was a median improvement in PFS of under 2 months, a subpopulation of patients were shown to significantly benefit from the addition of immunotherapy. The Phase III KEYNOTE-966 (NCT04003636) study investigating the addition of pembrolizumab to gemcitabine and cisplatin demonstrated an improvement in OS in the first-line setting. Dr Kim highlights the importance of biomarker analysis to uncover which patients benefit from immunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
